News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vanderbilt University and Bristol-Myers Squibb Company (BMY) Sign Collaboration Agreement to Develop Novel Treatments for Parkinson’s Disease


9/21/2012 10:09:15 AM

NASHVILLE, Tenn. & NEW YORK--(BUSINESS WIRE)--Vanderbilt University and Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES